{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/OKYO",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# OKYO Pharma Ltd (NASDAQ: OKYO) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nOKYO Pharma Ltd is listed on NASDAQ under the ticker OKYO. Its ISIN is USG6724L1165. Its LEI is not on the record, because no GLEIF record carries the exact legal name in jurisdiction US. Its security type is recorded as non-operating entity type (other). Its segment is not on the record. Its sector is 2836 Biological Products, (No Diagnostic Substances). Its jurisdiction is not on the record. Its status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 88 filings in the twelve months from 2025-11-08 to 2026-11-08, across 47 filing days. The filings comprise 28 directors' dealings, 4 prospectuses, 11 regulatory filings and 45 results. The median gap between filing days is 4.0 days. The latest filing is a results filing dated 2026-11-05, 3 days before the record date of 2026-11-08. The NASDAQ median cadence gap is 6.0 days across 4,359 issuers, and the NASDAQ median filings count is 52, with a median latency of 5.0 days. The sector median cadence gap is 5.5 days across 176 issuers, the sector median filings count is 65.5, and the sector median latency is 4.0 days.\n\n## Auditor\n\nThe auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. Its location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nSix research houses are named on the issuer's investor-relations page: H.C Wainwright & CO, Lucid, Piper Sandler, B Riley, Goldman Research Company and Goldman Research.\n\n## Open research\n\nSix openly published research notes are on the record. Piper Sandler & Co. published notes dated 2026-08-01, 2026-07-01 and 2026-02-19. H.C. Wainwright & Co. published a note dated 2026-01-29. B. Riley Securities published a note dated 2025-12-08. Lucid Capital Markets published a note dated 2025-07-31.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe vintage is sealed. The sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The earliest sealed date of the market is 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n14 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0001849296.json (identity.name)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/OKYO (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://okyopharma.com/investors/analyst-coverage/ (coverage)\n- https://okyopharma.com/wp-content/uploads/2026/08/Piper-Note-August-2026.pdf (open research)\n- https://okyopharma.com/wp-content/uploads/2026/07/Piper-July-2026-Update.pdf (open research)\n- https://okyopharma.com/wp-content/uploads/2026/02/OKYO-Piper-Report-Feb-26.pdf (open research)\n- https://okyopharma.com/wp-content/uploads/2026/01/OKYO-HCW-FDA-Endorses-Planned-Phase-2b_3-Trial-in-Neuropathic-Corneal-Jan-26.pdf (open research)\n- https://okyopharma.com/wp-content/uploads/2025/12/OKYO-B-RIley-Initiation-PT-5.pdf (open research)\n- https://okyopharma.com/wp-content/uploads/2025/07/OKYO-Initiation-Report-by-Lucid-7-31-25.pdf (open research)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/OKYO (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/OKYO",
  "coverage": {
   "count": 6,
   "houses": [
    {
     "house": "H.C Wainwright & CO",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/investors/analyst-coverage/",
     "state": "sourced"
    },
    {
     "house": "Lucid",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/investors/analyst-coverage/",
     "state": "sourced"
    },
    {
     "house": "Piper Sandler",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/investors/analyst-coverage/",
     "state": "sourced"
    },
    {
     "house": "B Riley",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/investors/analyst-coverage/",
     "state": "sourced"
    },
    {
     "house": "Goldman Research Company",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/investors/analyst-coverage/",
     "state": "sourced"
    },
    {
     "house": "Goldman Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/investors/analyst-coverage/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://okyopharma.com/investors/analyst-coverage/",
     "result": "read: 6 of 10 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 176,
     "median_cadence_gap_days": 5.5,
     "median_filings": 65.5,
     "median_latency_days": 4,
     "name": "2836 Biological Products, (No Diagnostic Substances)"
    }
   },
   "by_type": {
    "directors_dealings": 28,
    "prospectus": 4,
    "regulatory_filing": 11,
    "results": 45
   },
   "cadence_median_gap_days": 4,
   "filing_days": 47,
   "filings": 88,
   "latency_days": 3,
   "latest": [
    {
     "category": "6-K",
     "date": "2026-11-05",
     "source": "https://www.sec.gov/Archives/edgar/data/1849296/000149315226050047/form6-k.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-10-06",
     "source": "https://www.sec.gov/Archives/edgar/data/1849296/000149315226045836/form6-k.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-09-29",
     "source": "https://www.sec.gov/Archives/edgar/data/1849296/000149315226044760/form6-k.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-09-09",
     "source": "https://www.sec.gov/Archives/edgar/data/1849296/000149315226041864/form6-k.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-09-08",
     "source": "https://www.sec.gov/Archives/edgar/data/1849296/000149315226041686/form6-k.htm",
     "title": "6-K — 6-K",
     "type": "results"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/OKYO",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-05",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "USG6724L1165"
   },
   "jurisdiction": {
    "market": "US",
    "state": "not_on_record"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001849296.json",
    "state": "sourced",
    "value": "OKYO Pharma Ltd"
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001849296.json",
    "state": "sourced",
    "value": "2836 Biological Products, (No Diagnostic Substances)"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0001849296.json",
    "state": "sourced",
    "value": "Non-operating entity type (other)"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "OKYO"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:a2b937dae9e9667a474a5ff9ac267d33b4aa230f455cce4aa2cdf6b6e0033280",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [
    {
     "date": "2026-08-01",
     "kind": "issuer-sponsored",
     "publisher": "Piper Sandler & Co.",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/wp-content/uploads/2026/08/Piper-Note-August-2026.pdf",
     "state": "sourced",
     "title": "Mgmt Meeting Takeaways: Compelling Risk/Reward Setup; Execution in Focus"
    },
    {
     "date": "2026-07-01",
     "kind": "issuer-sponsored",
     "publisher": "Piper Sandler & Co.",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/wp-content/uploads/2026/07/Piper-July-2026-Update.pdf",
     "state": "sourced",
     "title": "Recent Regulatory Update Provides Solid Path to Potential Value Creation"
    },
    {
     "date": "2026-02-19",
     "kind": "issuer-sponsored",
     "publisher": "Piper Sandler & Co.",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/wp-content/uploads/2026/02/OKYO-Piper-Report-Feb-26.pdf",
     "state": "sourced",
     "title": "Can Urcosimod Offer Relief For NCP?"
    },
    {
     "date": "2026-01-29",
     "kind": "issuer-sponsored",
     "publisher": "H.C. Wainwright & Co.",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/wp-content/uploads/2026/01/OKYO-HCW-FDA-Endorses-Planned-Phase-2b_3-Trial-in-Neuropathic-Corneal-Jan-26.pdf",
     "state": "sourced",
     "title": "FDA Endorses Planned Phase 2b/3 Trial in Neuropathic Corneal Pain; Reiterate Buy"
    },
    {
     "date": "2025-12-08",
     "kind": "issuer-sponsored",
     "publisher": "B. Riley Securities",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/wp-content/uploads/2025/12/OKYO-B-RIley-Initiation-PT-5.pdf",
     "state": "sourced",
     "title": "OKYO Pharma Limited (OKYO – $1.91*)"
    },
    {
     "date": "2025-07-31",
     "kind": "issuer-sponsored",
     "publisher": "Lucid Capital Markets",
     "read_by": "the note's link answers (200 application/pdf); a document, not read as text",
     "read_date": "2026-11-11",
     "source": "https://okyopharma.com/wp-content/uploads/2025/07/OKYO-Initiation-Report-by-Lucid-7-31-25.pdf",
     "state": "sourced",
     "title": "Developing a Novel Drug for Severe Eye Pain; Initiating with a Buy Rating and a $13 Price Target"
    }
   ],
   "state": "found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/OKYO",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:a2b937dae9e9667a474a5ff9ac267d33b4aa230f455cce4aa2cdf6b6e0033280",
 "path": "/us/NASDAQ/OKYO",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "OKYO Pharma Ltd is listed on NASDAQ under the ticker OKYO. Its ISIN is USG6724L1165. Its LEI is not on the record, because no GLEIF record carries the exact legal name in jurisdiction US. Its security type is recorded as non-operating entity type (other). Its segment is not on the record. Its sector is 2836 Biological Products, (No Diagnostic Substances). Its jurisdiction is not on the record. Its status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 88 filings in the twelve months from 2025-11-08 to 2026-11-08, across 47 filing days. The filings comprise 28 directors' dealings, 4 prospectuses, 11 regulatory filings and 45 results. The median gap between filing days is 4.0 days. The latest filing is a results filing dated 2026-11-05, 3 days before the record date of 2026-11-08. The NASDAQ median cadence gap is 6.0 days across 4,359 issuers, and the NASDAQ median filings count is 52, with a median latency of 5.0 days. The sector median cadence gap is 5.5 days across 176 issuers, the sector median filings count is 65.5, and the sector median latency is 4.0 days.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. Its location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The issuer is listed and not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "Six research houses are named on the issuer's investor-relations page: H.C Wainwright & CO, Lucid, Piper Sandler, B Riley, Goldman Research Company and Goldman Research.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "Six openly published research notes are on the record. Piper Sandler & Co. published notes dated 2026-08-01, 2026-07-01 and 2026-02-19. H.C. Wainwright & Co. published a note dated 2026-01-29. B. Riley Securities published a note dated 2025-12-08. Lucid Capital Markets published a note dated 2025-07-31.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The vintage is sealed. The sealed years that hold the issuer are 2021, 2022, 2023, 2024, 2025 and 2026. The earliest sealed date of the market is 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "14 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.name",
   "source": "https://data.sec.gov/submissions/CIK0001849296.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/OKYO"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://okyopharma.com/investors/analyst-coverage/"
  },
  {
   "for": "open research",
   "source": "https://okyopharma.com/wp-content/uploads/2026/08/Piper-Note-August-2026.pdf"
  },
  {
   "for": "open research",
   "source": "https://okyopharma.com/wp-content/uploads/2026/07/Piper-July-2026-Update.pdf"
  },
  {
   "for": "open research",
   "source": "https://okyopharma.com/wp-content/uploads/2026/02/OKYO-Piper-Report-Feb-26.pdf"
  },
  {
   "for": "open research",
   "source": "https://okyopharma.com/wp-content/uploads/2026/01/OKYO-HCW-FDA-Endorses-Planned-Phase-2b_3-Trial-in-Neuropathic-Corneal-Jan-26.pdf"
  },
  {
   "for": "open research",
   "source": "https://okyopharma.com/wp-content/uploads/2025/12/OKYO-B-RIley-Initiation-PT-5.pdf"
  },
  {
   "for": "open research",
   "source": "https://okyopharma.com/wp-content/uploads/2025/07/OKYO-Initiation-Report-by-Lucid-7-31-25.pdf"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/OKYO"
  }
 ],
 "title": "OKYO Pharma Ltd (OKYO) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}